Skip to main content
. 2018 Oct 30;2018(10):CD008319. doi: 10.1002/14651858.CD008319.pub3

Postnikov 2007.

Methods 2‐arm cross‐over design.
Duration: 14 days.
Participants 15 children with CF aged 7 ‐ 17 years.
Interventions Twice‐daily versus once‐daily amikacin.
Dose: 15 mg/kg/day ‐ 20 mg/kg/day in combination with ceftazidime or meropenem.
Outcomes Lung function (FVC, FEV1), P aeruginosa colonies, nephrotoxicity, ototoxicity, serum levels of amikacin.
Measured on day 1 and day 14.
Notes Not clear if inhaled or IV.